KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $570000.0.

  • Neogenomics' Free Cash Flow rose 13670.32% to $570000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.0 million, marking a year-over-year increase of 2074.66%. This contributed to the annual value of -$34.0 million for FY2024, which is 1085.49% down from last year.
  • Per Neogenomics' latest filing, its Free Cash Flow stood at $570000.0 for Q3 2025, which was up 13670.32% from $14.0 million recorded in Q2 2025.
  • Neogenomics' 5-year Free Cash Flow high stood at $14.0 million for Q2 2025, and its period low was -$37.3 million during Q1 2022.
  • Over the past 5 years, Neogenomics' median Free Cash Flow value was -$13.6 million (recorded in 2021), while the average stood at -$14.1 million.
  • Per our database at Business Quant, Neogenomics' Free Cash Flow tumbled by 62318.7% in 2021 and then skyrocketed by 162076.17% in 2025.
  • Over the past 5 years, Neogenomics' Free Cash Flow (Quarter) stood at -$31.8 million in 2021, then soared by 74.12% to -$8.2 million in 2022, then surged by 230.51% to $10.7 million in 2023, then tumbled by 116.77% to -$1.8 million in 2024, then surged by 131.68% to $570000.0 in 2025.
  • Its Free Cash Flow stands at $570000.0 for Q3 2025, versus $14.0 million for Q2 2025 and -$29.8 million for Q1 2025.